Monoclonal Antibody and Oral Antiviral Treatment of SARS-CoV-2 Infection in US Nursing Homes

Nursing home residents are at high risk for severe infection from SARS-CoV-2 and should be prioritized for antiviral treatment. However, the overall use of antivirals among nursing home residents is low and does not match their elevated risk. There are several barriers to antiviral use in nursing ho...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	JAMA : the journal of the American Medical Association 2023-08, Vol.330 (6), p.561-563
Hauptverfasser:	McGarry, Brian E, Sommers, Benjamin D, Wilcock, Andrew D, Grabowski, David C, Barnett, Michael L
Format:	Artikel
Sprache:	eng
Schlagworte:	Antibodies, Monoclonal - therapeutic use Antiviral agents Antiviral Agents - administration & dosage Antiviral Agents - therapeutic use Antiviral drugs COVID-19 COVID-19 - therapy COVID-19 Drug Treatment - methods Familiarity Health risks Health services Humans Letter Letters Monoclonal antibodies Nurses Nursing Homes Online First Research Letter SARS-CoV-2 Severe acute respiratory syndrome coronavirus 2
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Nursing home residents are at high risk for severe infection from SARS-CoV-2 and should be prioritized for antiviral treatment. However, the overall use of antivirals among nursing home residents is low and does not match their elevated risk. There are several barriers to antiviral use in nursing homes, including limited access, changing authorizations and recommendations for monoclonal antibodies, patient and physician preferences, lack of familiarity with these medications, and high treatment costs. This study investigates the use of COVID-19 antiviral treatments in US nursing homes and the facility characteristics that are associated with their use.
ISSN:	0098-7484 1538-3598
DOI:	10.1001/jama.2023.12945